Figure 6.
PRT-treated platelet transfusion may induce early Treg-cell activity but no indicators of T-cell anergy. Splenocytes from mice described in Figure 3 were evaluated for markers of regulatory T cells and T-cell anergy. Representative gating selected for CD3+ CD4+ T cells that were positive for CTLA-4+ or TGF-β+ (A), regulatory FoxP3+ (B), regulatory FoxP3+/CD25+ (C), a subset of regulatory FoxP3+ CD25+ cells that were CTLA-4Hi or TGF-βHi (D), and anergic CD3+ CD4+ T cells by CD44+/FoxP3− folate receptor 4 (FR4)Hi/CD73Hi events (E). Frequencies (middle) and total numbers (right) are plotted. Notation indicates significance between groups. Data from 2 independent experiments (n = 5 per group) are shown, and bars indicate mean and standard deviation. *P < .05, **P < .01, ***P < .001, ****P < .0001.

PRT-treated platelet transfusion may induce early Treg-cell activity but no indicators of T-cell anergy. Splenocytes from mice described in Figure 3 were evaluated for markers of regulatory T cells and T-cell anergy. Representative gating selected for CD3+ CD4+ T cells that were positive for CTLA-4+ or TGF-β+ (A), regulatory FoxP3+ (B), regulatory FoxP3+/CD25+ (C), a subset of regulatory FoxP3+ CD25+ cells that were CTLA-4Hi or TGF-βHi (D), and anergic CD3+ CD4+ T cells by CD44+/FoxP3 folate receptor 4 (FR4)Hi/CD73Hi events (E). Frequencies (middle) and total numbers (right) are plotted. Notation indicates significance between groups. Data from 2 independent experiments (n = 5 per group) are shown, and bars indicate mean and standard deviation. *P < .05, **P < .01, ***P < .001, ****P < .0001.

Close Modal

or Create an Account

Close Modal
Close Modal